Irinotecan and radiation in combined-modality therapy for solid tumors

ONCOLOGY

Volumn 15, Issue 7 SUPPL. 8, 2001, Pages 22-28

  Choy, Hak ^a   Macrae, Rob ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DNA TOPOISOMERASE; DRUG DERIVATIVE; ENZYME INHIBITOR; IRINOTECAN;

ADJUVANT THERAPY; DRUG ADMINISTRATION; DRUG ANTAGONISM; FEMALE; GASTROINTESTINAL TUMOR; HEAD AND NECK TUMOR; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; NEOPLASM; REVIEW; UTERINE CERVIX TUMOR;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; DNA TOPOISOMERASES, TYPE I; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; GASTROINTESTINAL NEOPLASMS; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASMS; RADIOTHERAPY, ADJUVANT; UTERINE CERVICAL NEOPLASMS;

EID: 0035406843     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (3)

1. Greenlee RT, Hill-Harmon MB, Taylor M, et al: Cancer statistics 2001. CA Cancer J Clin 50:7-33, 2001.
2. Stevens CW, Lee JS, Cox J, et al: Novel approaches to locally advanced unresectable non-small cell lung cancer. Radiother Oncol 55(1)11-18, 2000.
3. Steele GG, Peckham MI: Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity. Int J Radiat Oncol Biol Phys 5:85-91, 1979.